The Experts below are selected from a list of 234 Experts worldwide ranked by ideXlab platform

Colin S. Mcardle - One of the best experts on this subject based on the ideXlab platform.

  • a prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss
    British Journal of Cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, Peter Ogorman, C E Wright, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of Megestrol Acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.

  • A prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
    British journal of cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, C E Wright, P O'gorman, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P

Donald C Mcmillan - One of the best experts on this subject based on the ideXlab platform.

  • a prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss
    British Journal of Cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, Peter Ogorman, C E Wright, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of Megestrol Acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.

  • A prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
    British journal of cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, C E Wright, P O'gorman, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P

Charles Lawrence Loprinzi - One of the best experts on this subject based on the ideXlab platform.

  • Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia
    2016
    Co-Authors: Charles Lawrence Loprinzi, Neil M Ellison, Laureen M Athmann, Ann Marie Dose, Larry P Ebbert, James A Mailliard, Daniel J Schaid, James E, Steven P. Johnson, L H Geeraerts
    Abstract:

    Preliminary information has suggested that Megestrol Acetate leads to appetite stimulation and nonfluid weight gain in patients with breast cancer, other cancers, and AIDS. Pursu-ant to this, we developed a randomized, double-blind, place-bo-controlled trial of Megestrol Acetate in patients with can-cer-associated anorexia and cachexia. We randomly assigned 133 eligible patients to receive 800 mg of Megestrol Acetate per day or a placebo. Patients assigned to Megestrol Acetate more frequently reported improved appetite (P =.003) and food intake (P =.009) when compared with patients receiving the placebo. A weight gain of 15 lb or more over baseline was seen in 11 of 67 (16%) patients receiving Megestrol Acetate com-pared with one of 66 (2%) given the placebo (P =.003). Patients receiving Megestrol Acetate reported significantly less nausea (13 % vs. 38 %; P =.001) and emesis (8 % vs. 25 %

  • long term use of Megestrol Acetate by cancer survivors for the treatment of hot flashes
    Cancer, 1998
    Co-Authors: Susan K Quella, Nancy L Vaught, W L Dekrey, Tammy Fischer, R Gwen N Finck, R Nancy N Pierson, Charles Lawrence Loprinzi, Jeff A. Sloan, Thomas M Pisansky
    Abstract:

    BACKGROUND Hot flashes are often a troublesome symptom in breast carcinoma survivors and men with prostate carcinoma who have undergone androgen deprivation therapy. A previous clinical study demonstrated that, on a short term basis, low dose Megestrol Acetate markedly reduced hot flashes and was well tolerated. Little information has been available regarding the long term use of low dose Megestrol Acetate for hot flashes. METHODS Patients previously enrolled on a randomized placebo-controlled trial that evaluated the short term use of Megestrol Acetate for hot flashes were contacted and interviewed by telephone. RESULTS A total of 132 persons were contacted. Nine percent of the patients discontinued Megestrol Acetate after resolution of their hot flashes. Forty-five percent of the patients contacted were continuing to utilize Megestrol Acetate approximately 3 years beyond the conclusion of the 1992 study. Three-quarters of these patients were utilizing ≤20 mg of Megestrol Acetate per day. Potential toxicities attributed to Megestrol Acetate included episodes of chills, appetite stimulation/weight gain, vaginal bleeding, and carpal tunnel syndrome symptoms. CONCLUSIONS A substantial proportion of patients continue to use Megestrol Acetate for periods of up to 3 years or longer with continued control of hot flashes. This treatment appears to be relatively well tolerated. Cancer 1998;82:1784-8. © 1998 American Cancer Society.

  • Megestrol Acetate for the prevention of hot flashes.
    The New England journal of medicine, 1994
    Co-Authors: Charles Lawrence Loprinzi, John C. Michalak, Ann Marie Dose, Susan K Quella, Tammy Fischer, Alan K Hatfield, Judith R. O'fallon, Robert A. Nelimark, Claudia Johnson, Nancy E. Klatt
    Abstract:

    Background Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent Megestrol Acetate can ameliorate hot flashes in both groups of patients. Methods The patients included 97 women with a history of breast cancer and 66 men with prostate cancer who had undergone androgen-deprivation therapy. All patients had experienced bothersome hot flashes (median number per day at base line, 6.1 for the women and 8.4 for the men). After a one-week pretreatment observation period, the patients received Megestrol Acetate (20 mg twice daily) for four weeks, followed by placebo for four weeks, or vice versa in a double-blind manner as determined by pretreatment randomization. The patien...

  • phase iii evaluation of four doses of Megestrol Acetate as therapy for patients with cancer anorexia and or cachexia
    Journal of Clinical Oncology, 1993
    Co-Authors: Charles Lawrence Loprinzi, John C. Michalak, Laureen M Athmann, Loren K Tschetter, Alan K Hatfield, James A Mailliard, Richard M. Goldberg, Daniel J Schaid, Roscoe F Morton
    Abstract:

    PURPOSESeveral placebo-controlled randomized clinical trials have demonstrated that Megestrol Acetate can result in appetite stimulation and nonfluid weight gain in patients with cancer anorexia/cachexia. The present trial was designed to compare Megestrol Acetate doses ranging from 160 to 1,280 mg/d.METHODSThis trial randomized 342 assessable patients with cancer anorexia/cachexia to receive oral Megestrol Acetate at doses of 160, 480, 800, or 1,280 mg/d. Patients were evaluated monthly by history, examination, patient-completed questionnaires, and serum albumin levels.RESULTSThe data demonstrate that there is a positive dose-response effect for Megestrol Acetate on appetite stimulation (P < or = .02). In concert, there was a trend for more nonfluid weight gain with higher drug doses. Megestrol Acetate was well tolerated in this group of patients with advanced malignant disease.CONCLUSIONThe positive dose-response effect that we observed for Megestrol Acetate on appetite stimulation supports both our pre...

  • Phase III evaluation of four doses of Megestrol Acetate as therapy for patients with cancer anorexia and/or cachexia
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993
    Co-Authors: Charles Lawrence Loprinzi, John C. Michalak, Laureen M Athmann, Loren K Tschetter, Alan K Hatfield, James A Mailliard, Richard M. Goldberg, Daniel J Schaid, Roscoe F Morton
    Abstract:

    PURPOSESeveral placebo-controlled randomized clinical trials have demonstrated that Megestrol Acetate can result in appetite stimulation and nonfluid weight gain in patients with cancer anorexia/cachexia. The present trial was designed to compare Megestrol Acetate doses ranging from 160 to 1,280 mg/d.METHODSThis trial randomized 342 assessable patients with cancer anorexia/cachexia to receive oral Megestrol Acetate at doses of 160, 480, 800, or 1,280 mg/d. Patients were evaluated monthly by history, examination, patient-completed questionnaires, and serum albumin levels.RESULTSThe data demonstrate that there is a positive dose-response effect for Megestrol Acetate on appetite stimulation (P < or = .02). In concert, there was a trend for more nonfluid weight gain with higher drug doses. Megestrol Acetate was well tolerated in this group of patients with advanced malignant disease.CONCLUSIONThe positive dose-response effect that we observed for Megestrol Acetate on appetite stimulation supports both our pre...

Stephen J Wigmore - One of the best experts on this subject based on the ideXlab platform.

  • a prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss
    British Journal of Cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, Peter Ogorman, C E Wright, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of Megestrol Acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.

  • A prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
    British journal of cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, C E Wright, P O'gorman, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P

Kenneth C H Fearon - One of the best experts on this subject based on the ideXlab platform.

  • a prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss
    British Journal of Cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, Peter Ogorman, C E Wright, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of Megestrol Acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.

  • A prospective randomized study of Megestrol Acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
    British journal of cancer, 1999
    Co-Authors: Donald C Mcmillan, Stephen J Wigmore, Kenneth C H Fearon, C E Wright, P O'gorman, Colin S. Mcardle
    Abstract:

    The use of Megestrol Acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of Megestrol Acetate and placebo with Megestrol Acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to Megestrol Acetate/placebo or Megestrol Acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the Megestrol Acetate/placebo group compared with an increase (median 2.3 kg) in the Megestrol Acetate/ibuprofen group (P